Cytokinetics CYTK
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Cytokinetics (CYTK) Core Market Data and Business Metrics
Latest Closing Price
$40.25Price-Earnings Ratio
-7.48Total Outstanding Shares
118.41 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
350 Oyster Point Boulevard, South San Francisco, CA, 94080
Historical Stock Splits
If you bought 6 shares of CYTK before June 25, 2013, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| June 25, 2013 | 1-for-6 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,540,969 Shares | 9.23 | 3/14/2025 | 14,220,519 Shares |
| 1,749,349 Shares | 8.04 | 2/28/2025 | 14,072,458 Shares |
| 2,204,930 Shares | 6.83 | 2/14/2025 | 15,069,465 Shares |
| 1,197,757 Shares | 11.4 | 1/31/2025 | 13,653,135 Shares |
| 1,141,143 Shares | 12.3 | 1/15/2025 | 14,030,843 Shares |
| 1,265,925 Shares | 10.83 | 12/31/2024 | 13,706,782 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-745.37 Million |
| Net Cash Flow | $-52.80 Million |
| Net Cash Flow From Financing Activities, Continuing | $1.10 Billion |
| Net Cash Flow From Operating Activities | $-404.36 Million |
| Net Cash Flow From Financing Activities | $1.10 Billion |
| Net Cash Flow From Operating Activities, Continuing | $-404.36 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-576.40 Million |
| Nonoperating Income/Loss | $44.11 Million |
| Basic Earnings Per Share | $-5.38 |
| Net Income/Loss Attributable To Parent | $-576.40 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Revenues | $3.22 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-570.14 Million |
| Other Comprehensive Income/Loss | $6.26 Million |
| Comprehensive Income/Loss | $-570.14 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Noncontrolling Interest | $0 |
| Current Liabilities | $109.81 Million |
| Other Non-current Liabilities | $720.21 Million |
| Long-term Debt | $619.95 Million |
| Equity Attributable To Parent | $-13.91 Million |
| Other Non-current Assets | $353.24 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||